Andere Sprachen Medigen Biotechnology Corp.

Aktien

3176

TW0003176004

3176

Schlusskurs Taipei Exchange Andere Börsenplätze 00:00:00 16.07.2024			% 5 Tage	% 1. Jan.
42.95 ^TWD	-0.69%		-7.14%	-4.13%

04.07.	Medigen erhält Genehmigungsschreiben des Ministeriums für Gesundheit und Soziales, das bestätigt, dass die Zellverarbeitungsanlage mit der Good Tissue Practice konform ist	CI
06.06.	Medigen Biotechnology Corp. gibt bekannt, dass Taiwan Mohw eine neue Version des gemeinsamen Projekts zur autologen Therapie mit natürlichen Killerzellen des Unternehmens und des Wanfang-Krankenhauses genehmigt hat	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Medigen Receives Approval Letter from Ministry of Health and Welfare Confirming Its Cell Processing Unit Is Compliant with Good Tissue Practice	04.07.
Medigen Biotechnology Corp. Announces Taiwan Mohw Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by the Company and Wanfang Hospital	06.06.
Medigen Biotechnology Corp. and Oncolys BioPharma Enroll First Participant in Investigator-Initiated Phase II Clinical Trial	03.06.
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
The Ministry of Health and Welfare Approves Collaborative Autologous Gamma-Delta T Cell Therapy Project by Medigen Biotechnology Corp. and Chi Mei Hospital	29.03.
Taiwan MOHW Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by Medigen Biotechnology Corp. and Changhua Christian Hospital	26.03.
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	15.03.
Medigen Biotechnology Corp. Announces Appointment of Chieh-Liang Lin as Chief Scientific Officer	11.03.
Medigen Biotechnology Corp. Applies to the Taiwan Food and Drug Administration for Phase I/Ii Clinical Trial Ofallogeneic Natural Killer Cells (Magicell-NK)	29.02.
Medigen Biotechnology Corp. Announces That the Ministry of Health and Welfare Has Approved the Collaborative Autologous Gamma-Delta T Cell Therapy Project by the Company and Changhua Christian Hospital	16.02.
Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan	07.02.
The Ministry of Health and Welfare Approves the Collaborative Autologous Gamma-Deltat Cell Therapy Project by Medigen Biotechnology Corp.And Taichung Tzu Chi Hospital	11.01.
Medigen Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11.11.
Medigen Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11.08.23
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15.05.23
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	31.03.23
Medigen Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15.11.22
Medigen Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12.08.22
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	16.05.22
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	30.03.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Medigen Biotechnology Corp.

Aktien

3176

TW0003176004

3176

Andere Sprachen

Filter